{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dupilumab+300+mg&page=2", "query": { "intervention": "Dupilumab 300 mg", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dupilumab+300+mg&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T00:25:48.277Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04345367", "title": "Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Abrocitinib 200 mg", "type": "DRUG" }, { "name": "Dupilumab 300 mg", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 727, "start_date": "2020-06-11", "completion_date": "2021-07-13", "has_results": true, "last_update_posted_date": "2022-07-08", "last_synced_at": "2026-09-29T00:25:48.277Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04345367" }, { "nct_id": "NCT05347771", "title": "Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 240, "start_date": "2022-05-04", "completion_date": "2027-03-15", "has_results": false, "last_update_posted_date": "2026-01-20", "last_synced_at": "2026-09-29T00:25:48.277Z", "location_count": 8, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05347771" }, { "nct_id": "NCT06116526", "title": "Dupilumab De-escalation in Pediatric Atopic Dermatitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Dupilumab - Discontinuation", "type": "DRUG" }, { "name": "Dupilumab - Dose Reduction", "type": "DRUG" }, { "name": "Dupilumab - Standard Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 30, "start_date": "2024-04-01", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-09-29T00:25:48.277Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06116526" }, { "nct_id": "NCT01859988", "title": "Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2013-05", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2017-08-28", "last_synced_at": "2026-09-29T00:25:48.277Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01859988" }, { "nct_id": "NCT04678856", "title": "Dupilumab in CRSsNP", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Rhinosinusitis Without Nasal Polyps", "Sinusitis", "Chronic Sinusitis", "Sinus Disorder", "Respiratory Disorder" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2020-12-02", "completion_date": "2024-01-29", "has_results": true, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-09-29T00:25:48.277Z", "location_count": 11, "location_summary": "Roseville, California • Stockton, California • Denver, Colorado + 7 more", "locations": [ { "city": "Roseville", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Columbia", "state": "Missouri" }, { "city": "Papillion", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04678856" }, { "nct_id": "NCT04180488", "title": "Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Spontaneous Urticaria" ], "interventions": [ { "name": "Dupilumab SAR231893", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "non sedating H1-antihistamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "6 Years to 80 Years" }, "enrollment_count": 397, "start_date": "2019-12-11", "completion_date": "2024-10-25", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-09-29T00:25:48.277Z", "location_count": 16, "location_summary": "Los Angeles, California • Sarasota, Florida • Sweetwater, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Sweetwater", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04180488" }, { "nct_id": "NCT01854047", "title": "An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "ICS/LABA therapy", "type": "DRUG" }, { "name": "Salbutamol/albuterol", "type": "DRUG" }, { "name": "Levosalbutamol/levalbuterol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 776, "start_date": "2013-06", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-09-29T00:25:48.277Z", "location_count": 50, "location_summary": "Fullerton, California • Huntington Beach, California • Los Angeles, California + 38 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01854047" }, { "nct_id": "NCT04296864", "title": "Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atopic Keratoconjunctivitis" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Andover Eye Associates", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2020-02-10", "completion_date": "2025-01", "has_results": false, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-09-29T00:25:48.277Z", "location_count": 20, "location_summary": "Los Angeles, California • Littleton, Colorado • Hollywood, Florida + 17 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Pittsburg", "state": "Kansas" }, { "city": "Andover", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04296864" }, { "nct_id": "NCT03389893", "title": "Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atopic Dermatitis (AD)" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 72, "start_date": "2018-07-25", "completion_date": "2020-09-09", "has_results": true, "last_update_posted_date": "2021-10-04", "last_synced_at": "2026-09-29T00:25:48.277Z", "location_count": 9, "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 6 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03389893" }, { "nct_id": "NCT02277743", "title": "Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Dermatitis, Atopic" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo (for Dupilumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 671, "start_date": "2014-10", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2017-11-21", "last_synced_at": "2026-09-29T00:25:48.277Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Clovis", "state": "California" }, { "city": "Lomita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02277743" } ] }